3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
4
Thoracic
3
Other hematologic neoplasm
3
Lymphoid
2
Head & Neck
2
CNS
2
Endocrine
1
Dermatologic
1
Conditions
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lymphoproliferative Disorders
1
Hematologic Neoplasms
1
Glioma
1
Brain Neoplasms
1
Interventions
pembrolizumab
65
Nivolumab
58
Ipilimumab
32
Cyclophosphamide
22
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
cemiplimab
13
fludarabine
12
Opdualag
12
binimetinib
10
Blood Specimen Collection
10
aldesleukin
9
Radiosurgery
9
encorafenib
8
Interleukin-2
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Radiotherapy
5
Disulfides
5
Bevacizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
entrectinib
×
Dermatologic
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled